Human Formulations

Sitagliptin Phosphate Tablets 25 mg

Sitagliptin Phosphate Tablets 25 mg is a tablet formulated with Sitagliptin Phosphate 25 mg. The listed active ingredient profile is Sitagliptin Phosphate, placing the product in the oral antidiabetic category. The formulation contains one or more oral gl

Therapeutic RangesDiabetic Range Single Ingredient Tablet
Sterile injectable formulation

Product information

Product Line
Human Formulations
Category
Therapeutic Ranges, Diabetic Range
Dosage Form
Tablet
Product Type
Single Ingredient

Available strengths

Sitagliptin Phosphate 25 mgSitagliptin Phosphate 50mgSitagliptin Phosphate 100mg

Description

Sitagliptin Phosphate Tablets 25 mg is a tablet formulated with Sitagliptin Phosphate 25 mg. The listed active ingredient profile is Sitagliptin Phosphate, placing the product in the oral antidiabetic category. The formulation contains one or more oral glucose-lowering medicines used in clinician-directed management of type 2 diabetes mellitus. The source identifies the dosage form as tablet with not specified presentation. For website cataloguing, the composition, strength, dosage form and formulation characteristics should be displayed prominently and consistently. The product description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and professional judgement. Prescription status, warnings, interactions, adverse effects and dosing or application instructions must be checked against the current approved product label. Manufacturer, licence, storage, shelf-life, reconstitution where applicable, and market-specific regulatory details should be added only from verified product documentation.
WHO-GMP Sourced
Sterile Supply
Regulatory Documentation
Quality Assured